


-40-

WHAT IS CLAIMED IS:

1. A compound structurally represented by Formula I




- 5 or pharmaceutically acceptable salts thereof wherein:

R¹ is

-CH₂NR³R⁴,

-CONR³R⁴,



10 R² is

-Hydrogen;




-NH-(C₁-C₆) alkyl,

-NH-(C₁-C₄) alkylene-phenyl,

-NH(C₃-C₆)cycloalkyl,

15

-NR³R⁴,



wherein;

20

R³ is hydrogen,

-(C₁-C₄) alkyl,

-41-


R⁴ is-(C₁-C₄) alkyl,-(C₁-C₄) alkylene -phenyl,

wherein R³ and R⁴ can cyclize to form, together with the nitrogen to which they are attached, a five or six-membered ring, wherein optionally one of the carbons of the ring formed by said nitrogen, R³, and R⁴, is replaced by a nitrogen or oxygen, and wherein said ring is optionally further substituted by R⁵,
and

R⁵ is hydrogen,

- 10 -(C₁-C₄) alkyl, wherein optionally R⁵ forms a 3 to five membered ring with the nitrogen containing ring to which it is attached,
 -(C₁-C₄) alkylene -N-pyrrolidinyl,
 -(C₁-C₄) alkylene -N- piperidinyl.

2. A compound structurally represented by Formula II,




(II)

or pharmaceutically acceptable salts thereof wherein:



Z is -carbonyl-, or -CH₂-,R² is

- 20 -Hydrogen,
 -NH-(C₁-C₆) alkyl,
 -NH-(C₁-C₄) alkylene-phenyl,
 -NH(C₃-C₆)cycloalkyl,
 -NR³R⁴,



25

-42-



wherein;

R^3 is hydrogen,

5 $-(C_1-C_4)$ alkyl,

R^4 is

$-(C_1-C_4)$ alkylene -phenyl,

wherein R^3 and R^4 can cyclize to form, together with the nitrogen to which they are attached, a five or six-membered ring, wherein optionally one of the carbons of the ring formed by said nitrogen, R^3 , and R^4 , is replaced by a nitrogen or oxygen, and wherein said ring is optionally further substituted by R^5 ,

and

R^5 is hydrogen,






$-(C_1-C_4)$ alkyl, wherein optionally R^5 forms a 3 to five membered ring with the nitrogen containing ring to which it is attached,

$-(C_1-C_4)$ alkylene -N-pyrrolidinyl,






$-(C_1-C_4)$ alkylene -N- piperidinyl.

3. The compound of claim 1, wherein R^1 is $CONR^3R^4$, and R^3 and R^4 cyclize to form, together with the nitrogen to which they are attached, a five membered ring, and said ring is further substituted by $-CH_2-$ pyrrolidinyl.
4. The compound of claim 1, wherein R^1 is $CH_2NR^3R^4$, and R^3 and R^4 cyclize to form, together with the nitrogen to which they are attached, a five membered ring, and said ring is further substituted by $-CH_2-$ pyrrolidinyl.
5. The compound of claim 3 wherein R^2 is NR^3R^4 , and R^3 and R^4 cyclize to form, together with the nitrogen to which they are attached, a five membered ring.
6. The compound of claim 4 wherein R^2 is NR^3R^4 , and R^3 and R^4 cyclize to form, together with the nitrogen to which they are attached, a five membered ring.
7. The compound of claim 1, further represented by any one of formula (Example 1) to (Example 18) selected from the group consisting of:






-43-

Example Number	
1	
2	
3	
4	
5	





-44-

6	
7	 
8	
9	

-45-

10	
11	
12	
13	
14	

-46-

15	
16	 Chiral
17	 Chiral
18	 Chiral

or a pharmaceutically acceptable salt or solvate thereof.

8. A pharmaceutical composition which comprises a compound of any of claims 1-7 and a pharmaceutically acceptable carrier.

5 9. A method for treatment or prevention of a cognitive disorder which comprises administering to a subject in need of such treatment or prevention an effective amount of a compound of any of Claims 1-7.

10. The method of Claim 9 wherein the antagonist is a pharmaceutical composition of claim 8.

10 11. A method for treatment or prevention of obesity which comprises administering to a subject in need of such treatment or prevention an effective amount of a compound of any of Claims 1-7.

-47-

12. The method of Claim 11 wherein the antagonist is a pharmaceutical composition of claim 8.
13. A method for treatment or prevention of a wakefulness disorder which comprises administering to a subject in need of such treatment or prevention an effective
5 amount of a compound of any of Claims 1-7.
14. The method of Claim 13 wherein the antagonist is a pharmaceutical composition of claim 8.
15. A method for treatment or prevention of a disorder or disease in which inhibition of the histamine H3 receptor has a beneficial effect which comprises
10 administering to a subject in need of such treatment or prevention an effective amount of a compound of any of claims 1-7.